PHARMACOGENETICS AND GLAUCOMA THERAPEUTICS

药物遗传学和青光眼治疗

• 批准号: 7376549
• 负责人: Sayoko E Moroi
• 金额: $ 4.75万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-05 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376549
• 关键词: eye; genetics; glaucoma

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It is well known that individuals show variable responses to drug treatments. For example, in patients taking drugs to treat glaucoma, some individuals have a good response with eye pressure lowering to a drug, while others show only a marginal response, and yet still others suffer adverse effects from the same drug. Such variable responses to drugs among patients are caused by a combination of biological mechanisms, environmental factors, and the genetic make up of the individual patient. The science behind pharmacogenetics is based on understanding the relationship between gene variations, called polymorphisms, and individual variations in drug response. These genetic polymorphisms may be potential markers for predicting drug response in an individual patient. The goal of Dr. Moroi's project is to determine whether genetic variations in the glaucoma drug target genes and related pathways account for the observed variation in eye pressure response to glaucoma drugs used to lower eye pressure in the treatment of glaucoma. In this study, Dr. Moroi will study the individual response to the glaucoma medications using a noninvasive procedure called fluorophotometry. This instrument can measure the eye's change in fluid production in response to glaucoma medications.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。众所周知，个体对药物治疗的反应可变。例如，在服用药物治疗青光眼的患者中，有些人对降低眼压的反应良好，而另一些人仅表现出边际反应，而其他人则遭受同一药物的不良影响。患者中对药物的这种可变反应是由生物学机制，环境因素和个体患者的遗传组成的组合引起的。药物遗传学背后的科学是基于理解基因变异，称为多态性和药物反应中个体变异之间的关系。这些遗传多态性可能是预测个别患者药物反应的潜在标志物。 Moroi博士项目的目标是确定青光眼药物靶基因的遗传变异和相关途径是否解释了观察到的对青光眼药物的眼压反应的变化，用于降低降低青光眼治疗的眼压。在这项研究中，Moroi博士将使用称为荧光测定法的无创方法研究对青光眼药物的个人反应。该仪器可以响应青光眼药物来测量眼睛的液体产生变化。